Literature DB >> 26391021

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.

Wen-zhao Zhong1, Jian Su1, Fang-ping Xu2, Hao-ran Zhai1, Xu-chao Zhang1, Xue-ning Yang1, Zhi-yong Chen1, Zhi-hong Chen1, Wei Li1, Song Dong1, Qing Zhou1, Jin-ji Yang1, Yan-hui Liu2, Yi-long Wu3.   

Abstract

OBJECTIVES: Most lung adenocarcinomas consist of mixtures of histological subtypes harboring different frequencies of driver gene mutations. However, little is known about intratumoral heterogeneity(ITH) within histologically heterogeneous primary lung cancers. Investigating key driver genes in respective morphological pattern is crucial to personalized treatment.
METHODS: Morphologically different areas within the same surgically resected adenocarcinomas were extracted from tissues to analyze gene status in each growth pattern. Driver genes, epidermal growth factor receptor (EGFR), KRAS and EML4-ALK, were assessed by assays with different sensitivities.
RESULTS: Seventy-nine consecutive eligible patients harboring a driver gene (EGFR=65; KRAS=10; EML4-ALK=4) were enrolled. For EGFR mutations, ITH occurred in 13.3% (8/60) by direct sequencing (DS) and 1.7% (1/60) by amplification refractory mutation system (ARMS) (P=0.016) among adenocarcinomas, but consistent within five adeno-squamous cell carcinomas by both methods. ITH among KRAS mutations were detected in 20% (2/10) by DS, whereas consistent (10/10) by high resolution melting. No discrepancies in EML4-ALK rearrangements existed according to fluorescence in situ hybridization.
CONCLUSION: Rare ITHs of EGFR/KRAS/EML4-ALK alterations within histologically heterogeneous primary lung adenocarcinomas existed by methods with higher sensitivity. Discrepancies might be due to abundance of mutant tumor cells and detection assays.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EML4-ALK; Epidermal growth factor receptor; Intratumor heterogeneity; KRAS; Lung cancer

Mesh:

Substances:

Year:  2015        PMID: 26391021     DOI: 10.1016/j.lungcan.2015.09.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  3 in total

1.  Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.

Authors:  Zhong-Yi Dong; Hao-Ran Zhai; Qing-Yi Hou; Jian Su; Si-Yang Liu; Hong-Hong Yan; Yang-Si Li; Zhi-Yong Chen; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Oncologist       Date:  2017-01

2.  Clonally-related primary ALK rearranged adenocarcinoma and associated metastatic lesions.

Authors:  You-Cai Zhu; Yun-Te Deng; Wen-Xian Wang; Chun-Wei Xu; Wu Zhuang; Kai-Qi Du
Journal:  Thorac Cancer       Date:  2018-05-08       Impact factor: 3.500

3.  Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.

Authors:  Tingyou Zhang; Yu Zhang; Lin Zhou; Shanshan Deng; Meijuan Huang; Yuncong Liu; Yongmei Liu; Youlin Gong; Jiang Zhu; Jianxin Xue; Yuju Bai; Hu Ma; Yan Zhang; Min Yu; Yanying Li; Yongsheng Wang; Bingwen Zou; Xiaojuan Zhou; Weigang Xiu; Feifei Na; Yong Xu; Feng Peng; Jin Wang; You Lu
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.